Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
Dermatol Ther. 2022 Oct;35(10):e15306. doi: 10.1111/dth.15306. Epub 2022 Aug 12.
Psoriasis is a multifactorial, chronic, auto- inflammatory disease, with a worldwide prevalence of around 2%, subtended by robust genetic predisposition and autoimmune pathogenic traits. The disease, mainly involving the skin and joints, is featured by erythemato-squamous lesions, with a chronic relapsing course and relevant systemic comorbidities. Apremilast is a novel oral agent that has recently been made available to dermatologists for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Although it is considered as relatively safe molecule with few contraindications, experience with Apremilast in the real-world setting for cancer patients with moderate-to-severe plaque psoriasis is lacking. Hence, we report the real-life experience in patients with psoriasis and a history of cancer who underwent treatment with Apremilast for 104 weeks.
银屑病是一种多因素、慢性、自身炎症性疾病，全球患病率约为 2%，具有强大的遗传易感性和自身免疫发病特征。该疾病主要累及皮肤和关节，表现为红斑鳞屑性皮损，具有慢性复发过程和相关的系统性合并症。阿普米司特是一种新型口服药物，最近已被皮肤科医生用于治疗中重度斑块状银屑病和银屑病关节炎。尽管它被认为是一种相对安全的药物，禁忌症较少，但在癌症合并中重度斑块状银屑病患者的真实世界环境中使用阿普米司特的经验尚缺乏。因此，我们报告了 104 周内接受阿普米司特治疗的有银屑病和癌症病史的患者的真实临床经验。
